These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 23358123)
1. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Macconell L; Pencek R; Li Y; Maggs D; Porter L Diabetes Metab Syndr Obes; 2013; 6():31-41. PubMed ID: 23358123 [TBL] [Abstract][Full Text] [Related]
2. Corrigendum to "Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury" [Neurobiology of Disease Volume 124 (2019) 439-453 /YNBDI_4338]. Bader M; Li Y; Lecca D; Rubovitch V; Tweedie D; Glotfelty E; Rachmany L; Kim HK; Choi HI; Hoffer BJ; Pick CG; Greig NH; Kim DS Neurobiol Dis; 2024 Jun; ():106563. PubMed ID: 38890024 [No Abstract] [Full Text] [Related]
3. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115 [TBL] [Abstract][Full Text] [Related]
4. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672 [TBL] [Abstract][Full Text] [Related]
5. Risk of cardiovascular disease: the effects of diabetes and anti-diabetic drugs - a nested case-control study. Gejl M; Starup-Linde J; Scheel-Thomsen J; Gregersen S; Vestergaard P Int J Cardiol; 2015 Jan; 178():292-6. PubMed ID: 25465309 [TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin in patients with type 2 diabetes mellitus. Filippatos TD; Liberopoulos EN; Elisaf MS Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954 [TBL] [Abstract][Full Text] [Related]
7. Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Charles ED; Neuschwander-Tetri BA; Pablo Frias J; Kundu S; Luo Y; Tirucherai GS; Christian R Obesity (Silver Spring); 2019 Jan; 27(1):41-49. PubMed ID: 30520566 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770 [TBL] [Abstract][Full Text] [Related]
9. Targeting the incretin system in obesity and type 2 diabetes mellitus. Ansari S; Khoo B; Tan T Nat Rev Endocrinol; 2024 Aug; 20(8):447-459. PubMed ID: 38632474 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind clinical trial of a herbal formulation (GlycaCare-II) for the management of type 2 diabetes in comparison with metformin. Majeed M; Majeed A; Nagabhusahnam K; Mundkur L; Paulose S Diabetol Metab Syndr; 2021 Nov; 13(1):132. PubMed ID: 34789340 [TBL] [Abstract][Full Text] [Related]
11. The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Wang J; Jin X; An P; Yu S; Mu Y J Diabetes Res; 2019; 2019():8083417. PubMed ID: 31772945 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications. Heile M; Wyne K; Billings LK; Cannon A; Handelsman Y; Shannon M J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S42-S52. PubMed ID: 30156446 [TBL] [Abstract][Full Text] [Related]
13. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Coveleskie K; Kilpatrick LA; Gupta A; Stains J; Connolly L; Labus JS; Sanmiguel C; Mayer EA Obes Sci Pract; 2017 Dec; 3(4):434-445. PubMed ID: 29259802 [TBL] [Abstract][Full Text] [Related]
14. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Genovese S; Mannucci E; Ceriello A Adv Ther; 2017 Aug; 34(8):1791-1814. PubMed ID: 28674957 [TBL] [Abstract][Full Text] [Related]
15. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Courtney H; Nayar R; Rajeswaran C; Jandhyala R Diabetes Metab Syndr Obes; 2017; 10():79-87. PubMed ID: 28331351 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study. Henry RR; Klein EJ; Han J; Iqbal N Diabetes Technol Ther; 2016 Nov; 18(11):677-686. PubMed ID: 27525540 [TBL] [Abstract][Full Text] [Related]